T
Tzy-Jyun Yao
Researcher at Harvard University
Publications - 71
Citations - 4584
Tzy-Jyun Yao is an academic researcher from Harvard University. The author has contributed to research in topics: Metastatic breast cancer & Chemotherapy. The author has an hindex of 32, co-authored 67 publications receiving 4182 citations. Previous affiliations of Tzy-Jyun Yao include Memorial Sloan Kettering Cancer Center & University of Hong Kong.
Papers
More filters
Journal ArticleDOI
Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma
TL;DR: The Hong Kong Liver Cancer (HKLC) classification had significantly better ability than the BCLC system to distinguish between patients with specific overall survival times and identified subsets of BCLCs intermediate- and advanced-stage patients for more aggressive treatments than what were recommended by the B CLC system, which improved survival outcomes.
Journal ArticleDOI
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.
Michelle Z. Xu,Tzy-Jyun Yao,Nikki P. Lee,Irene Oi-Lin Ng,Yuk-Tat Chan,Lars Zender,Scott W. Lowe,Ronnie T.P. Poon,John M. Luk +8 more
TL;DR: Investigation of the clinical significance of YAP in HCC and its prognostic values in predicting survival and tumor recurrence found it to be related to hepatocarcinogenesis.
Journal Article
GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients after Administration with Immunological Adjuvant QS-21
Friedhelm Helling,Shengle Zhang,Shang A,Sucharita Adluri,Michele Jones Calves,R. Rao Koganty,Longenecker Bm,Tzy-Jyun Yao,Herbert F. Oettgen,Philip O. Livingston +9 more
TL;DR: The finding that QS-21 significantly increased the immunogenicity of GM2-KLH suggests that it may do the same for other conjugate vaccines, many of which are currently used without adjuvant.
Journal ArticleDOI
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
Andrew D. Seidman,Bonnie Reichman,John Crown,Tzy-Jyun Yao,Violante Currie,T Hakes,Clifford A. Hudis,Theresa Gilewski,José Baselga,P. Forsythe +9 more
TL;DR: The lack of impact of prior doxorubicin therapy on the likelihood of subsequent response to paclitaxel suggests an important role for this agent in the treatment of refractory metastatic breast cancer.
Journal Article
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Teresa Gilewski,Sucharita Adluri,Govindaswami Ragupathi,Shengle Zhang,Tzy-Jyun Yao,Katherine S. Panageas,ME Moynahan,Alan N. Houghton,Larry Norton,Philip O. Livingston +9 more
TL;DR: This M UC1-KLH conjugate plus QS-21 was immunogenic and well tolerated in breast cancer patients and additional trials are ongoing to determine the optimal MUC1 peptide for use in larger clinical trials.